Overview

Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

Status:
Terminated
Trial end date:
2020-04-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of RO7239361 in boys with Duchenne Muscular Dystrophy with any genetic mutation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche